Timothy Leiner1, Suzanne C. Gerretsen2,
Thierry le Maire2, Stephan Miller3, Siegfried Thurnher4,
Christoph U. Herborn5, Henrik J. Michaely6, Harald
Kramer7, Angelo Vanzulli8, Josef Vymazal9,
Martin Wasser10
1Radiology, Maastricht University
Hospital, Maastrict, Netherlands; 2Radiology, Catharina Hospital,
Eindhoven, Netherlands; 3Radiology, Eberhard-Karls University,
Tbingen, Germany; 4Radiology, Hospital of St. John of God,
Vienna, Austria; 5Radiology, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany; 6Institute of Clinical
Radiology, University Hospital Mannheim, Mannheim, Germany; 7Radiology,
Ludwig Maximilians University, Munich, Germany; 8Hospital Niguarda
Ca Granda, Milan, Italy; 9Radiology, Na Homolce Hospital, Prague,
Czech Republic; 10Radiology, Leiden University Medical Center,
Leiden, Netherlands
Equivalent
0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine
were compared in terms of diagnostic performance in 397 segments from 96
patients with suspected peripheral arterial occlusive disease undergoing
CE-MRA, using DSA as the reference standard. Three blinded readers rated the
diagnostic performance of gadobenate dimeglumine significantly better in
terms of sensitivity, specificity, and overall accuracy. In addition,
significantly higher PPV and NPV values were noted after gadobenate
dimeglumine compared to gadopentetate dimeglumine, despite the equivalent
dose.